View Filing Data

Print Document View Excel Document

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Mar. 31, 2015	May 05, 2015
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Entity Registrant Name	ASSEMBLY BIOSCIENCES, INC.
Entity Central Index Key	0001426800
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	ASMB
Entity Common Stock, Shares Outstanding		17,177,106

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2015	Dec. 31, 2014
Current assets
Cash	$ 96,054,082	$ 29,091,113
Other current assets	283,836	125,284
Total current assets	96,337,918	29,216,397
Property, plant and equipment, net	173,248	156,441
Security deposits	98,899	115,005
Intangible assets	29,000,000	29,000,000
Goodwill	12,737,350	12,737,350
Total assets	138,347,415	71,225,193
Current liabilities
Accounts payable	1,250,843	907,601
Accrued expenses	877,540	146,420
Total current liabilities	2,128,383	1,054,021
Contingent license fee
Deferred tax liabilities	11,600,000	11,600,000
Total liabilities	13,728,383	12,654,021
Stockholders' equity
Preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding at March 31, 2015 and December 31, 2014, respectively	0	0
Common stock, $0.001 par value; 50,000,000 shares authorized; 16,250,814 shares and 10,672,059 shares issued, and outstanding at March 31, 2015 and December 31, 2014, respectively	16,251	10,672
Additional paid-in capital	267,259,806	194,072,572
Accumulated deficit	(142,657,025)	(135,512,072)
Total stockholders' equity	124,619,032	58,571,172
Total liabilities and stockholders' equity	$ 138,347,415	$ 71,225,193

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2015	Dec. 31, 2014
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	16,250,814	10,672,059
Common stock, shares outstanding	16,250,814	10,672,059

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Operating expenses:
Research and development	$ 3,834,434	$ 2,973,690
General and administrative	3,368,784	1,136,461
Total operating costs and expenses	7,203,218	4,110,151
Loss from operations	(7,203,218)	(4,110,151)
Other income
Interest income	58,265	40,234
Total other income	58,265	40,234
Net loss	$ (7,144,953)	$ (4,069,917)
Net loss per share, basic and diluted (in dollars per share)	$ (0.64)	$ (0.92)
Weighted average common shares outstanding, basic and diluted (in shares)	11,176,580	4,418,940

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities
Net loss	$ (7,144,953)	$ (4,069,917)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	13,904	1,266
Stock-based compensation	2,585,780	254,717
Changes in assets and liabilities:
Other current assets	(158,552)	(195,522)
Accounts payable	283,242	(1,179,419)
Accrued expenses	731,120	3,814
Other assets	16,106	0
Net cash used in operating activities	(3,673,353)	(5,185,061)
Cash flows from investing activities
Purchase of fixed assets	(30,711)	(2,589)
Net cash used in investing activities	(30,711)	(2,589)
Cash flows from financing activities
Proceeds from issuance of common stock, net of cost	70,499,993	1,763,104
Proceeds from the exercise of stock options	167,040	0
Net cash provided by financing activities	70,667,033	1,763,104
Net increase (decrease) in cash	66,962,969	(3,424,546)
Cash at the beginning of the period	29,091,113	27,061,268
Cash at the end of the period	96,054,082	23,636,722
Supplemental schedule of non-cash financing activities
Accrued offering cost related to the issuance of common stock	(60,000)	0
Conversion of preferred stock to common stock	$ 0	$ 440

CONDENSED CONSOLDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY - 3 months ended Mar. 31, 2015 - USD ($)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2014	$ 58,571,172	$ 10,672	$ 194,072,572	$ (135,512,072)
Balance (in shares) at Dec. 31, 2014		10,672,059
Proceeds from common stock sold net of costs	70,499,993	$ 5,556	70,494,437	0
Proceeds from common stock sold net of costs ( in Shares)		5,555,555
Accrued offering cost related to the issuance of common stock	$ (60,000)	$ 0	(60,000)	0
Exercise of stock options (in shares)	23,200	23,200
Exercise of stock options	$ 167,040	$ 23	167,017	0
Stock-based compensation	2,585,780	0	2,585,780	0
Net loss	(7,144,953)	0	0	(7,144,953)
Balance at Mar. 31, 2015	$ 124,619,032	$ 16,251	$ 267,259,806	$ (142,657,025)
Balance (in shares) at Mar. 31, 2015		16,250,814

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Business

3 Months Ended

Mar. 31, 2015

Organization, Business and Basis Of Presentation [Abstract]

Overview

Note 1 – Business:

Overview

Assembly Biosciences, Inc. (“Assembly” or the “Company”) is a biopharmaceutical company committed to developing novel oral therapies for the cure of intractable infectious diseases, focusing on the hepatitis B virus (HBV) and C. difficile-associated diarrhea (CDAD). Our HBV-Cure research team is working on discovering and developing multiple core protein allosteric modifiers (CpAMs) with the potential to modulate the HBV core protein - a polyfunctional essential viral protein - at multiple complementary points in the viral lifecycle. The goal is to eradicate the infection with an orally-administered regimen. Our CDAD program is based on the premise that an oral capsule containing specific bacteria grown in monoculture and manufactured under pharmaceutical-like GMP conditions might be effective in providing the therapeutic benefits of fecal microbiota transplant (FMT) therapy in a form that is economically viable and scalable for use.

2014 Highlights

On July 11, 2014, Assembly Biosciences was formed by the merger of private company Assembly Pharmaceuticals, Inc. and Nasdaq-listed Ventrus Biosciences, Inc. The merger resulted in a shift in strategic focus, the addition of a new lead drug development program and changes in personnel. In connection with the merger, the Company’s Board of Directors and stockholders approved a 1-for-5 reverse stock split of the Company’s common stock. The reverse stock split became effective on July 11, 2014. All share and per share amounts in the consolidated financial statements and notes thereto have been retroactively adjusted for all periods presented to give effect to this reverse stock split, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital. In connection with the Merger, the shares of Assembly Pharmaceuticals, common stock issued and outstanding were converted into an aggregate of 4,008,848 shares of the Company’s common stock. Also pursuant to the terms of the Merger, the outstanding options to purchase shares of Assembly Pharmaceuticals, common stock were assumed by the Company and became exercisable for an aggregate of 621,651 shares of the Company’s common stock.

On October 6, 2014, the Company sold to various institutional investors an aggregate of 1,959,000 shares of common stock in a registered direct offering. The purchase price paid by the investors was $8.04 per share and an aggregate of approximately $14,963,000 in net proceeds were received.

2015 Highlights

On April 6, 2015, the underwriters exercised in full their option to purchase an additional 833,333 shares of our common stock at the public offering price of $13.50 per share, less underwriting discounts and commissions and offering expenses. Proceeds from the sale of shares on the exercise of the underwriters’ option (net of underwriters’ discount) were approximately $10.6 million.

The Company has not derived any revenue from product sales to date as the products have not been approved for sale by the FDA or any foreign regulatory agency. Since inception, the Company’s operations have been financed primarily through the sale of equity securities, the proceeds from the exercise of warrants and stock options and issuance of debt. The Company has incurred losses from operations and negative cash flows since inception and expects to continue to incur substantial losses for the next several years as it continues its product development efforts. Management believes the Company currently has sufficient funds to meet its operating requirements for at least the next twelve months. If the Company cannot generate significant cash from its operations, it intends to obtain any additional funding it requires through strategic relationships, public or private equity or debt financings, or other arrangements and it cannot assure such funding will be available on reasonable terms, if at all.

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2015

Summary Of Significant Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2 – Summary of Significant Accounting Policies:

Significant Accounting Policies

There have been no material changes in the Company’s significant accounting policies to those previously disclosed in the Company’s annual report on Form 10-K for the year ended December 31, 2014, which was filed with the SEC on March 12, 2015 and amended on March 16, 2015 (“2014 Annual Report”).

Basis of Presentation

The accompanying unaudited condensed consolidated interim financial statements include the accounts of the Company and its subsidiary from the date of its acquisition (July 11, 2014). Accordingly, the results of operations for the three months ended March 31, 2014 do not include the operations of Assembly Pharmaceuticals. All material intercompany balances and transactions have been eliminated.

The accompanying unaudited condensed financial statements as of March 31, 2015 and for the three months ended March 31, 2015 and 2014 have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and on the same basis as the Company prepares its annual audited consolidated financial statements. The condensed consolidated balance sheet as of March 31, 2015, condensed consolidated statements of operations for the three months ended March 31, 2015 and 2014, condensed consolidated statement of changes in stockholders’ equity for the three months ended March 31, 2015, and the condensed consolidated statements of cash flows for the three months ended March 31, 2015 and 2014 are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the three months ended March 31, 2015 are not necessarily indicative of results to be expected for the year ending December 31, 2015 or for any future interim period. The condensed balance sheet at December 31, 2014 has been derived from audited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed financial statements should be read in conjunction with the consolidated financial statements for the year ended December 31, 2014, and notes thereto included in the 2014 Annual Report.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Significant estimates inherent in the preparation of the accompanying financial statements include recoverability and useful lives of long-lived assets, the valuation allowance related to the Company’s deferred tax assets and the fair value of stock options and warrants granted to employees, consultants, directors, investors, licensors, placement agents and underwriters.

Certain of the Company’s estimates, including the carrying amount of the intangible assets, could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates and assumptions.

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606). The ASU provides for a single comprehensive model for use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance. The accounting standard is effective for interim and annual periods beginning after December 15, 2016 with no early adoption permitted. In April 2015, the FASB issued a proposal to defer the effective date of ASU 2014-09 by a year.

In June 2014, the FASB issued ASU 2014-12, Compensation-Stock Compensation (Topic 718). The ASU clarifies how entities should treat performance targets that can be achieved after the requisite service period of a share-based payment award. The accounting standard is effective for interim and annual periods beginning after December 15, 2015.

The FASB has issued ASU 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. The guidance, which is effective for annual reporting periods ending after December 15, 2016, with early adoption permitted, extends the responsibility for performing the going-concern assessment to management and contains guidance on how to perform a going-concern assessment and when going-concern disclosures would be required under GAAP. The Company is currently evaluating the impact of this ASU on its condensed consolidated financial statements.

Accounting standards that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s financial statements upon adoption.

Assembly Pharmaceuticals, Inc. Transaction

3 Months Ended

Mar. 31, 2015

Business Combinations [Abstract]

Assembly Pharmaceuticals, Inc. Transaction

Note 3 - Assembly Pharmaceuticals, Inc. Transaction:

On July 11, 2014, the Company completed the Assembly Merger, whereby Assembly Pharmaceuticals became the Company’s wholly-owned subsidiary. Pursuant to the terms of the Assembly Merger, the shares of Assembly Pharmaceuticals were converted into an aggregate of 4,008,848 shares of the Company’s common stock. Also pursuant to the terms of the Assembly Merger, the outstanding options to purchase shares of Assembly Pharmaceuticals were assumed by the Company and an aggregate of 621,651 shares of the Company’s common stock were reserved for issuance thereunder.

The allocation of the purchase price to the Assembly balance sheet is shown below:

Cash and cash equivalents	$	509,363
Other current assets		23,540
Equipment, net		10,350
In-process research and development		29,000,000
Goodwill		12,737,350
Security deposits		16,606
Total assets		42,297,209

Accrued expenses		874,113
Deferred tax liability		11,600,000
Total liabilities		12,474,113
Net assets acquired	$	29,823,096

The transaction was accounted for using the acquisition method. Accordingly, goodwill has been measured as the excess of the total consideration over the amounts assigned to the identifiable assets acquired and liabilities assumed including the related deferred tax liability.

On the acquisition date, the fair value of net assets acquired was $29,823,096. The fair value of stock issued to the Assembly Pharmaceuticals’ shareholders as part of the consideration of $29,064,148 was based on reference to quoted market values of the Company’s common stock as of the date of acquisition. The options assumed in the Assembly Merger were valued at $758,948. The following table presents the unaudited pro forma financial results, as if the Assembly Merger had been completed as of January 1, 2014.

Pro Forma

	Three Months Ended March 31,
	2014
Revenues	$	-
Net loss		(4,495,684)
Loss per share - basic and diluted	$	(0.54)

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

Goodwill and Intangible Assets

3 Months Ended

Mar. 31, 2015

Goodwill [Abstract]

Goodwill

Note 4 – Goodwill and Intangible Assets:

In July 2014, the Company completed its acquisition of Assembly Pharmaceuticals (Note 1 and 3). The fair value of consideration paid, common stock and assumed options, totaled $29,823,096, which net of amounts allocated to assets and liabilities acquired at fair value, resulted in an allocation to goodwill of $12,737,350. The Company also acquired certain indefinite-lived intangible assets related to Assembly Pharmaceuticals’ technology. The Company only has one operating segment.

Goodwill

Goodwill is not amortized for financial reporting purposes but is tested for impairment on an annual basis or when indications of impairment exist. No goodwill impairment losses have been recognized. Goodwill is not deductible for income tax purposes since the tax basis is $0. The Company will perform its annual impairment test of the carrying value of the Company’s goodwill each year on December 31.

There was no change in the net book value of goodwill from December 31, 2014 to March 31, 2015.

Intangible Assets

The intangible assets acquired are recorded as indefinite-lived asset and are not amortized for financial reporting purposes but are tested for impairment on an annual basis or when indications of impairment exist. No intangible assets impairment losses have been recognized. Intangible assets are not deductible for income tax purposes since the tax basis is $0. The Company will perform its annual impairment test of the carrying value of the Company’s intangible assets each year on December 31.

There was no change in intangible assets from December 31, 2014 to March 31, 2015.

Property, Plant and Equipment, Net

3 Months Ended

Mar. 31, 2015

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment Disclosure

Note 5 - Property, Plant and Equipment, Net:

Property, plant and equipment, consisted of the following:

	Useful Life (Years)		March 31, 2015		December 31, 2014
Computer hardware and software	3		75,226		75,196
Lab equipment	3 to 5		161,058		130,377
Office equipment	3 to 5		1,109		1,109
Total property, plant and equipment			237,393		206,682
Less: Accumulated depreciation and amortization			(64,145)		(50,241)
Property, plant and equipment, net		$	173,248	$	156,441

Depreciation expense for the three months ended March 31, 2015 and 2014 was $13,904 and $1,266, respectively, and was recorded in both research and development expense and general and administrative expense in the consolidated statements of operations.

Accrued Expenses

3 Months Ended

Mar. 31, 2015

Payables and Accruals [Abstract]

Accounts Payable and Accrued Liabilities Disclosure

Note 6 - Accrued Expenses:

Accrued expenses consisted of the following:

		March 31, 2015		December 31, 2014
Accrued expenses:
Salaries, bonuses and employee benefits	$	253,156	$	-
Severance accrued for former CEO		491,170		-
Professional fees		19,000		19,860
Research and development expenses		15,000		27,346
License maintenance fees		99,214		99,214
Total accrued expenses	$	877,540	$	146,420

Stockholders' Equity

3 Months Ended

Mar. 31, 2015

Stockholders' Transactions [Abstract]

Stockholders' Equity

Note 7 - Stockholders’ Equity:

Equity Financing

On March 19, 2015, the Company sold to various investors an aggregate of 5,555,555 shares of common stock in a public offering. The purchase price paid by the investors was $13.50 per share and an aggregate of approximately $70.5 million in net proceeds were received, after deducting underwriting discounts and commissions and estimated offering expenses. In addition, the Company granted the underwriters a 30-day option to purchase up to an additional 833,333 shares of common stock.

On April 6, 2015, the underwriters exercised in full their option to purchase an additional 833,333 shares of common stock at the public offering price of $13.50 per share, less underwriting discounts and commissions and offering expenses. The closing of the option exercise resulted in net proceeds of approximately $10.6 million. Exercise of the underwriters’ option increased the net proceeds (net of underwriters’ discount) of the public offering, from $70,500,000 to $81,000,000.

Options, Warrants and Restricted Stock Units

Options

The Company has two equity incentive plans available for the granting of equity awards. In July 2010, the stockholders approved the 2010 Stock Plan, under which, as of March 31 2015, there were outstanding options for an aggregate of 68,000 shares of common stock and an aggregate of 696,100 shares available for grant. In July 2014, the stockholders approved the 2014 Stock Incentive Plan (the “2014 Plan”), under which, as of March 31, 2015, there were options for an aggregate of 2,270,834 shares of common stock outstanding and 289,166 shares available for grant.

On February 10, 2015, pursuant to and subject to the available number of shares reserved under the 2014 Plan, the Company issued 12,500 incentive stock options with a term of 10 years and an exercise price of $9.42 to a new employee. One-third of the options will vest on the first anniversary of the vesting commencement date; the remainder will vest in two equal installments on the second and third anniversary of the vesting commencement date.

On February 10, 2015, Dr. Ellison transitioned to service as a consultant. The Company accelerated 266,667 of his options on March 3, 2015 in accordance with the original terms of his employment agreement. The exercise period for Dr. Ellison’s vested options were also extended until the end of their term, or July 9, 2024 in accordance with the original terms of his employment agreement. The remainders of 266,666 unvested options were forfeited in accordance with the original terms of his employment agreement.

On February 19, 2015, an employee exercised options to purchase 21,200 common shares under and pursuant to the 2014 Plan. The total purchase price was $152,640 with a price of $7.20 per share.

On February 24, 2015, an employee exercised options to purchase 2,000 common shares under and pursuant to the 2014 Plan. The total purchase price was $14,400 with a price of $7.20 per share.

A summary of the Company’s option activity and related information for the three-month period ended March31, 2015 is as follows:

	Number of Shares		Weighted Average Exercise Price		Total Intrinsic Value
Outstanding as of December 31, 2014		3,237,851	$	6.26	$	5,187,924
Granted		12,500		9.42		-
Exercised		(23,200)		7.20		140,128
Forfeited		(266,666)		7.20		-
Outstanding as of March 31, 2015		2,960,485	$	6.19	$	20,886,161
Options vested and exercisable		1,381,696	$	6.21	$	9,717,342

The fair value of the options granted for the three-month period ended March 31, 2015, was based on the following assumptions:

		Three Months Ended March 31,
		2015
Exercise price		9.42
Expected stock price volatility		92.64% - 105.03%
Risk-free rate of interest		1.49% - 2.53%
Term (years)		5.4 - 10.0

Estimated future stock-based compensation expense relating to unvested stock options is as follows:

	Future Stock Option Compensation Expense
Nine months ended 2015	$	3,033,545
2016		1,262,438
2017		44,645
Total	$	4,340,628

The weighted average remaining contractual life of options outstanding at March 31, 2015 is approximately 9.3 years.

Stock-based compensation expensed to research and development expense for the three months ended March 31, 2015 and 2014 was $1,055,430 and $(4,335) (including reversal of charges related to unvested options which were forfeited), respectively. Stock-based compensation expensed to general and administrative expense for the three months ended March 31, 2015 and 2014 was $1,530,350 and $259,052, respectively.

Loss per Common Share

Basic net loss per common share excludes dilution and is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity unless inclusion of such shares would be anti-dilutive. Since the Company has only incurred losses, basic and diluted net loss per share is the same. Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share for the three months ended March 31, 2015 and 2014 are as follows:

	Three Months Ended March 31,
	2015		2014
Non-vested restricted stock units		-		75,000
Warrants to purchase common stock		270,761		151,236
Options to purchase common stock		2,960,485		536,598
Total		3,231,246		762,834

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Commitments

3 Months Ended

Mar. 31, 2015

Commitments and Contingencies Disclosure [Abstract]

Commitments

Note 8 - Commitments:

Lease

As of March 31, 2015, the Company had offices in New York, NY with an $8,400 monthly payment. The lease expires in September 2015.

In January 2015, the Company entered into a lease in San Francisco, CA with a $36,145 monthly payment. The lease expires in December 2016.

Employment Agreements

The Company has employment agreements with its Chief Executive Officer and Chief Financial Officer which provide for an aggregate annual salary of approximately $780,500 in 2015.

Legal Proceedings

3 Months Ended

Mar. 31, 2015

Legal Matter Disclosure [Abstract]

Legal Proceedings

Note 9 - Legal Proceedings:

The Company is not a party to any legal proceedings and is not aware of any claims or actions pending or threatened against it. In the future, the Company might from time to time become involved in litigation relating to claims arising from our ordinary course of business.

Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2015

Summary Of Significant Accounting Policies [Abstract]

Significant Accounting Policies

Significant Accounting Policies

Basis of presentation

Basis of Presentation

Use of Estimates

Use of Estimates

Recent Accounting Pronouncements

Recent Accounting Pronouncements

Assembly Pharmaceuticals, Inc. Transaction (Tables)

3 Months Ended

Mar. 31, 2015

Assembly Pharmaceuticals, Inc. Transaction [Abstract]

Assembly Pharmaceuticals, Inc. Transaction

The allocation of the purchase price to the Assembly balance sheet is shown below:

Cash and cash equivalents	$	509,363
Other current assets		23,540
Equipment, net		10,350
In-process research and development		29,000,000
Goodwill		12,737,350
Security deposits		16,606
Total assets		42,297,209

Accrued expenses		874,113
Deferred tax liability		11,600,000
Total liabilities		12,474,113
Net assets acquired	$	29,823,096

Pro Forma

Pro Forma

	Three Months Ended March 31,
	2014
Revenues	$	-
Net loss		(4,495,684)
Loss per share - basic and diluted	$	(0.54)

Property, Plant and Equipment, Net (Tables)

3 Months Ended

Mar. 31, 2015

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment

Property, plant and equipment, consisted of the following:

	Useful Life (Years)		March 31, 2015		December 31, 2014
Computer hardware and software	3		75,226		75,196
Lab equipment	3 to 5		161,058		130,377
Office equipment	3 to 5		1,109		1,109
Total property, plant and equipment			237,393		206,682
Less: Accumulated depreciation and amortization			(64,145)		(50,241)
Property, plant and equipment, net		$	173,248	$	156,441

Accrued Expenses (Tables)

3 Months Ended

Mar. 31, 2015

Payables and Accruals [Abstract]

Schedule of Accrued Liabilities

Accrued expenses consisted of the following:

		March 31, 2015		December 31, 2014
Accrued expenses:
Salaries, bonuses and employee benefits	$	253,156	$	-
Severance accrued for former CEO		491,170		-
Professional fees		19,000		19,860
Research and development expenses		15,000		27,346
License maintenance fees		99,214		99,214
Total accrued expenses	$	877,540	$	146,420

Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2015

Stockholders' Transactions [Abstract]

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award

A summary of the Company’s option activity and related information for the three-month period ended March31, 2015 is as follows:

	Number of Shares		Weighted Average Exercise Price		Total Intrinsic Value
Outstanding as of December 31, 2014		3,237,851	$	6.26	$	5,187,924
Granted		12,500		9.42		-
Exercised		(23,200)		7.20		140,128
Forfeited		(266,666)		7.20		-
Outstanding as of March 31, 2015		2,960,485	$	6.19	$	20,886,161
Options vested and exercisable		1,381,696	$	6.21	$	9,717,342

Assumptions for Weighted Average Fair Value of Options Granted

The fair value of the options granted for the three-month period ended March 31, 2015, was based on the following assumptions:

		Three Months Ended March 31,
		2015
Exercise price		9.42
Expected stock price volatility		92.64% - 105.03%
Risk-free rate of interest		1.49% - 2.53%
Term (years)		5.4 - 10.0

Estimated Future Stock Based Expenses Relating to Unvested Stock Options

Estimated future stock-based compensation expense relating to unvested stock options is as follows:

	Future Stock Option Compensation Expense
Nine months ended 2015	$	3,033,545
2016		1,262,438
2017		44,645
Total	$	4,340,628

Schedule of Restricted Stock Units

	Three Months Ended March 31,
	2015		2014
Non-vested restricted stock units		-		75,000
Warrants to purchase common stock		270,761		151,236
Options to purchase common stock		2,960,485		536,598
Total		3,231,246		762,834

Business - Additional Information (Details) - USD ($)			1 Months Ended
Business - Additional Information (Details) - USD ($)	Apr. 06, 2015	Oct. 06, 2014	Mar. 19, 2015	Jul. 11, 2014	Mar. 31, 2015
Overview [Line Items]
Stock Issued During Period, Shares, New Issues		1,959,000
Shares Issued, Price Per Share		$ 8.04
Proceeds from Issuance of Common Stock		$ 14,963,000
Stock Issued During Period, Shares, Conversion of Convertible Securities				4,008,848
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number				621,651	1,381,696
Common Stock [Member]
Overview [Line Items]
Stock Issued During Period, Shares, New Issues			5,555,555
Shares Issued, Price Per Share			$ 13.50
Proceeds from Issuance of Common Stock			$ 70,500,000
Stock Issued During Period, Shares, Conversion of Convertible Securities				4,008,848
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number				621,651
Common Stock [Member] \| Subsequent Event [Member]
Overview [Line Items]
Stock Issued During Period, Shares, New Issues	833,333
Shares Issued, Price Per Share	$ 13.50
Proceeds from Issuance of Common Stock	$ 10,600,000

Assembly Pharmaceuticals, Inc. Transaction - Allocation of Purchase Price (Details) - USD ($)	Mar. 31, 2015	Dec. 31, 2014	Jul. 11, 2014
Cash and cash equivalents			$ 509,363
Other current assets			23,540
Equipment, net			10,350
In-process research and development			29,000,000
Goodwill			12,737,350
Security deposits	$ 98,899	$ 115,005	16,606
Total assets			42,297,209
Accrued expenses			874,113
Deferred tax liability			11,600,000
Total liabilities			12,474,113
Consideration Paid
Net assets acquired			$ 29,823,096

Assembly Pharmaceuticals, Inc. Transaction - Pro Forma (Details)	3 Months Ended
	Mar. 31, 2014 USD ($) $ / shares
Pro Forma
Revenues	$ 0
Net loss	$ (4,495,684)
Loss per share - basic and diluted \| $ / shares	$ (0.54)

Assembly Pharmaceuticals, Inc. Transaction - Additional Information (Details) - USD ($)	1 Months Ended
	Jul. 11, 2014	Mar. 31, 2015
Stock Issued During Period, Shares, Conversion of Convertible Securities	4,008,848
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	621,651	1,381,696
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net	$ 29,823,096
Fair value of options assumed	758,948
Noncash Or Part Noncash Acquisition Share Exchange Business Combination	$ 29,064,148

Goodwill and Intangible Assets - Additional Information (Details)	3 Months Ended
	Mar. 31, 2015 USD ($)
Business Combination, Consideration Transferred	$ 29,823,096
Allocation of goodwill	12,737,350
Business Acquisition, Goodwill, Expected Tax Deductible Amount	0
Business Acquisition, Intangible Expected Tax Deductible Amount	$ 0

Property, Plant and Equipment, Net (Details) - USD ($)	3 Months Ended
Property, Plant and Equipment, Net (Details) - USD ($)	Mar. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 237,393	$ 206,682
Less: Accumulated depreciation and amortization	(64,145)	(50,241)
Total property, plant and equipment	173,248	156,441
Computer hardware and software [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 75,226	75,196
Property, Plant and Equipment, Useful Life	3 years
Lab equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 161,058	130,377
Lab equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Lab equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 1,109	$ 1,109
Office Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Office Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years

Property, Plant and Equipment, Net - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Property, Plant and Equipment [Line Items]
Depreciation	$ 13,904	$ 1,266

Accrued Expenses (Details) - USD ($)	Mar. 31, 2015	Dec. 31, 2014
Accrued expenses:
Salaries, bonuses and employee benefits	$ 253,156	$ 0
Severance accrued for former CEO	491,170	0
Professional fees	19,000	19,860
Research and development expenses	15,000	27,346
License maintenance fees	99,214	99,214
Total accrued expenses	$ 877,540	$ 146,420

Stockholders' Equity - Option Activity and Related Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2015	Jul. 11, 2014
Shares
Option, Outstanding at beginning of period	3,237,851
Option, Granted	12,500
Option, Exercised	(23,200)
Option, Forfeited	(266,666)
Option, Outstanding at end of period	2,960,485
Options vested and exercisable	1,381,696	621,651
Weighted Average Exercise Price
Option, Outstanding at beginning of period	$ 6.26
Option, Granted	9.42
Option, Exercised	7.20
Option, Forfeited	7.2
Option, Outstanding at end of period	6.19
Option vested exercisable at end of period	$ 6.21
Aggregate Intrinsic Value
Option, Outstanding at beginning of period	$ 5,187,924
Option, Granted	0
Option, Exercised	140,128
Option, Forfeited	0
Option, Outstanding at end of period	20,886,161
Option vested exercisable at end of period	$ 9,717,342

Stockholders' Equity - Assumptions for Fair Value of Options Granted (Details)	3 Months Ended
	Mar. 31, 2015 $ / shares
Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]
Exercise price	$ 9.42
Maximum [Member]
Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]
Expected stock price volatility	105.03%
Risk-free rate of interest	2.53%
Term (years)	10 years
Minimum [Member]
Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]
Expected stock price volatility	92.64%
Risk-free rate of interest	1.49%
Term (years)	5 years 4 months 24 days

Stockholders' Equity - Estimated Future Stock-Based Compensation Expense Relating to Unvested Stock Options (Details)	Mar. 31, 2015 USD ($)
Stockholders Equity Note [Line Items]
Nine months ended 2015	$ 3,033,545
2016	1,262,438
2017	44,645
Total	$ 4,340,628

Stockholders' Equity - (Loss Per Common Share) (Details) - shares	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,231,246	762,834
Non Vested Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	75,000
Warrants To Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	270,761	151,236
Options To Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,960,485	536,598

Stockholders' Equity - Additional Information (Details) - USD ($)					1 Months Ended		3 Months Ended
	Apr. 06, 2015	Feb. 24, 2015	Feb. 10, 2015	Oct. 06, 2014	Mar. 19, 2015	Feb. 19, 2015	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Stockholders Equity Note [Line Items]
Stock Issued During Period, Shares, New Issues				1,959,000
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number							2,960,485		3,237,851
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price							$ 6.19		$ 6.26
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term							9 years 3 months 18 days
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross							12,500
Shares Issued, Price Per Share				$ 8.04
Proceeds From Issuance Initial Public Offering							$ 70,499,993	$ 1,763,104
Stock Issued During Period, Value, Stock Options Exercised							$ 167,040
2010 Plan
Stockholders Equity Note [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number							68,000
Common Stock, Capital Shares Reserved for Future Issuance							696,100
2014 Plan
Stockholders Equity Note [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number							2,270,834
Common Stock, Capital Shares Reserved for Future Issuance							289,166
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price			$ 9.42
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term			10 years
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross			12,500
Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award		2,000				21,200
Stock Issued During Period, Value, Stock Options Exercised		$ 14,400				$ 152,640
Share-based Compensation Arrangement by Share-based Payment Award, Per Share Weighted Average Price of Shares Purchased		$ 7.20				$ 7.20
Additional Paid-in Capital [Member]
Stockholders Equity Note [Line Items]
Stock Issued During Period, Value, Stock Options Exercised							$ 167,017
Common Stock [Member]
Stockholders Equity Note [Line Items]
Stock Issued During Period, Value, New Issues					$ 70,500,000
Stock Issued During Period, Shares, New Issues					5,555,555
Sale of Stock, Price Per Share					$ 13.50
Shares Issued, Price Per Share					$ 13.50
Stock Issued During Period, Value, Stock Options Exercised							23
Common Stock [Member] \| Subsequent Event [Member]
Stockholders Equity Note [Line Items]
Stock Issued During Period, Shares, New Issues	833,333
Shares Issued, Price Per Share	$ 13.50
Underwritten Public Offering [Member] \| Common Stock [Member]
Stockholders Equity Note [Line Items]
Stock Issued During Period, Value, New Issues	$ 10,600,000
Stock Issued During Period, Shares, New Issues	833,333
Shares Issued, Price Per Share	$ 13.50
Underwriters [Member] \| Common Stock [Member]
Stockholders Equity Note [Line Items]
Stock Issued During Period, Shares, New Issues					833,333
Dr Ellison [Member]
Stockholders Equity Note [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares			266,666
Accelerated Options			266,667
Maximum [Member] \| Underwritten Public Offering [Member] \| Common Stock [Member]
Stockholders Equity Note [Line Items]
Proceeds From Issuance Initial Public Offering	$ 81,000,000
Minimum [Member] \| Underwritten Public Offering [Member] \| Common Stock [Member]
Stockholders Equity Note [Line Items]
Proceeds From Issuance Initial Public Offering	$ 70,500,000
Research and Development Expense [Member]
Stockholders Equity Note [Line Items]
Stock based compensation expense							1,055,430	(4,335)
General and Administrative Expenses [Member]
Stockholders Equity Note [Line Items]
Stock based compensation expense							$ 1,530,350	$ 259,052

Commitments - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended
	Jan. 31, 2015	Mar. 31, 2015
Commitments and Contingencies Disclosure [Line Items]
Operating Leases, Rent Expense	$ 36,145	$ 8,400
Chief Executive Officer And Chief Financial Officer [Member]
Commitments and Contingencies Disclosure [Line Items]
Annual base Salary		$ 780,500